FDA 483 - UBI Pharma, Inc. - October 14, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
UBI Pharma Inc. was cited for significant deficiencies in its manufacturing and quality control processes for sterile injectable drug products. Issues include unqualified visual inspection equipment, inadequate control procedures for particulate matter, failures in aseptic processing, and a dysfunctional quality control unit that neglected complaint investigations and change control. These lapses resulted in the release of potentially compromised drug products to the US market.
ID · 3a306b84-362f-4c3e-848b-0abc60c4621f